{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:19:49Z","timestamp":1790957989569,"version":"4.1.0"},"reference-count":55,"publisher":"Pleiades Publishing Ltd","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biochemistry Moscow"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1134\/s0006297924060099","type":"journal-article","created":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T13:02:15Z","timestamp":1720098135000},"page":"1094-1108","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Design, in silico Evaluation, and Determination of Antitumor Activity of Potential Inhibitors Against Protein Kinases: Application to BCR-ABL Tyrosine Kinase"],"prefix":"10.1134","volume":"89","author":[{"given":"Elena V.","family":"Koroleva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasiya L.","family":"Ermolinskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanna V.","family":"Ignatovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yury V.","family":"Kornoushenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alesia V.","family":"Panibrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir I.","family":"Potkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander M.","family":"Andrianov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"137","published-online":{"date-parts":[[2024,7,4]]},"reference":[{"key":"2703_CR1","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1126\/science.2408149","volume":"247","author":"T. G. Lugo","year":"1990","unstructured":"Lugo, T. G., Pendergast, A. M., Muller, A. J., and Witte, O.\u00a0N. (1990) Tyrosine kinase activity and transformation potency of bcr-abl oncogene products, Science, 247, 1079-1082, \nhttps:\/\/doi.org\/10.1126\/science.2408149.","journal-title":"Science"},{"key":"2703_CR2","first-page":"2049","volume":"60","author":"M. W. Deininger","year":"2000","unstructured":"Deininger, M. W., Vieira, S., Mendiola, R., Schultheis, B., Goldman, J. M., and Melo, J.\u00a0V. (2000) BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia, Cancer Res., 60, 2049-2055.","journal-title":"Cancer Res."},{"key":"2703_CR3","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","volume":"113","author":"A. Quint\u00e1s-Cardama","year":"2009","unstructured":"Quint\u00e1s-Cardama, A., and Cortes, J. (2009) Molecular biology of bcr-abl1-positive chronic myeloid leukemia, Blood, 113, 1619-1630, \nhttps:\/\/doi.org\/10.1182\/blood-2008-03-144790.","journal-title":"Blood"},{"key":"2703_CR4","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","volume":"344","author":"B. J. Druker","year":"2001","unstructured":"Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M.,\u00a0Capdeville,\u00a0R., and Talpaz, M. (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome, N.\u00a0Eng. J. Med., 344, 1038-1042, \nhttps:\/\/doi.org\/10.1056\/NEJM200104053441402.","journal-title":"N.\u00a0Eng. J. Med."},{"key":"2703_CR5","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1053\/beha.2002.0233","volume":"15","author":"O. G. Ottmann","year":"2002","unstructured":"Ottmann, O. G., and Wassmann, B. (2002) Imatinib in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia: current status and evolving concepts, Best Pract. Res. Clin. Haematol., 15, 757-769, \nhttps:\/\/doi.org\/10.1053\/beha.2002.0233.","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"2703_CR6","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/s0959-8049(02)80600-1","volume":"38","author":"E. Buchdunger","year":"2002","unstructured":"Buchdunger, E., O\u2019Reilley, T., and Wood, J. (2002) Pharmacology of imatinib (STI571), Eur.\u00a0J. Cancer, 38, S28-S36, \nhttps:\/\/doi.org\/10.1016\/s0959-8049(02)80600-1.","journal-title":"Eur.\u00a0J. Cancer"},{"key":"2703_CR7","doi-asserted-by":"publisher","first-page":"879","DOI":"10.2165\/00003088-200544090-00001","volume":"44","author":"B. Peng","year":"2005","unstructured":"Peng, B., Lloyd, P., and Schran, H. (2005) Clinical pharmacokinetics of imatinib, Clin. Pharmacokinet., 44, 879-894, \nhttps:\/\/doi.org\/10.2165\/00003088-200544090-00001.","journal-title":"Clin. Pharmacokinet."},{"key":"2703_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0065-230X(04)91001-9","volume":"91","author":"B. J. Druker","year":"2004","unstructured":"Druker, B. J. (2004) Imatinib as a paradigm of targeted therapies, Adv. Cancer Res., 91, 1-30, \nhttps:\/\/doi.org\/10.1016\/S0065-230X(04)91001-9.","journal-title":"Adv. Cancer Res."},{"key":"2703_CR9","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1056\/NEJMoa011573","volume":"346","author":"H. Kantarjian","year":"2002","unstructured":"Kantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C., Gambacorti-Passerini, C., Niederwieser, D., Resta, D., Capdeville, R., Zoellner, U., Talpaz,\u00a0M., Druker, B., Goldman, J., O'Brien, S. G., Russell, N., Fischer, T., Ottmann, O., Cony-Makhoul, P., Facon, T., Stone, R., Miller, C., Tallman, M., Brown, R., Schuster, M., Loughran, T., Gratwohl, A., Mandelli, F., Saglio, G., Lazzarino, M., Russo, D., Baccarani, M., Morra, E., and International STI571 CML Study Group (2002) Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia, N.\u00a0Eng. J. Med., 346, 645-652, \nhttps:\/\/doi.org\/10.1056\/NEJMoa011573.","journal-title":"N.\u00a0Eng. J. Med."},{"key":"2703_CR10","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"B. J. Druker","year":"2006","unstructured":"Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W. N., Silver, R. T., Goldman, J. M., Stone, R. M., Cervantes, F., Hochhaus, A., Powell, B. L., Gabrilove,\u00a0J. L., Rousselot, P., Reiffers, J., Cornelissen, J. J., Hughes, T., Agis, H., Fischer, T., Verhoef, G., Shepherd, J., Saglio, G., Gratwohl, A., Nielsen, J. L., Radich, J. P., Simonsson, B., Taylor, K., Baccarani, M., So, C., Letvak,\u00a0L., Larson, R. A., and IRIS Investigators (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia, N.\u00a0Eng. J. Med., 355, 2408-2417, \nhttps:\/\/doi.org\/10.1056\/NEJMoa062867.","journal-title":"N.\u00a0Eng. J. Med."},{"key":"2703_CR11","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A. Hochhaus","year":"2017","unstructured":"Hochhaus, A., Larson, R. A., Guilhot, F., Radich, J. P., Branford, S., Hughes, T. P., Baccarani,\u00a0M., Deininger, M. W., Cervantes, F., Fujihara, S., Ortmann, C.-E., Menssen, H. D., Kantarjian, H., O'Brien, S. G., Druker, B. J., and IRIS Investigators (2017) Long-term outcomes of imatinib treatment for chronic myeloid leukemia, N.\u00a0Eng. J. Med., 376, 917-927, \nhttps:\/\/doi.org\/10.1056\/NEJMoa1609324.","journal-title":"N.\u00a0Eng. J. Med."},{"key":"2703_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0804-2","volume":"17","author":"K. S. Bhullar","year":"2018","unstructured":"Bhullar, K. S., Lagar\u00f3n, N. O., McGowan, E. M., Parmar, I., Jha, A., Hubbard, B. P., and Vasantha, R. H. P. (2018) Kinase-targeted cancer therapies: progress, challenges and future directions, Mol. Cancer, 17, 48, \nhttps:\/\/doi.org\/10.1186\/s12943-018-0804-2.","journal-title":"Mol. Cancer"},{"key":"2703_CR13","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.hoc.2017.04.007","volume":"31","author":"A. B. Patel","year":"2017","unstructured":"Patel, A. B., O\u2019Hare, T., and Deininger, M. W. (2017) Mechanisms of resistance to ABL kinase inhibition in chronic myeloid leukemia and the development of next generation ABL kinase inhibitors, Hematol. Oncol. Clin. North Am., 31, 589-612, \nhttps:\/\/doi.org\/10.1016\/j.hoc.2017.04.007.","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"2703_CR14","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1111\/cbdd.13801","volume":"97","author":"J. Liu","year":"2021","unstructured":"Liu, J., Zhang, Y., Huang, H., Lei, X., Tang, G., Cao, X., and Peng, J. (2021) Recent advances in Bcr-Abl tyrosine kinase inhibitors for overriding T315I mutation, Chem. Biol. Drug Des., 97, 649-664, \nhttps:\/\/doi.org\/10.1111\/cbdd.13801.","journal-title":"Chem. Biol. Drug Des."},{"key":"2703_CR15","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1134\/S1070428016020019","volume":"52","author":"E. V. Koroleva","year":"2016","unstructured":"Koroleva, E. V., Ignatovich, Z. I., Sinyutich, Y. V., and Gusak, K.\u00a0N. (2016) Aminopyrimidine derivatives as protein kinases inhibitors. Molecular design, synthesis, and biologic activity, Russ.\u00a0J. Org. Chem., 52, 139-177, \nhttps:\/\/doi.org\/10.1134\/S1070428016020019.","journal-title":"Russ.\u00a0J. Org. Chem."},{"key":"2703_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106552","volume":"187","author":"R. Roskoski Jr.","year":"2022","unstructured":"Roskoski, R., Jr. (2022) Properties of FDA-approved small molecule protein kinase inhibitors: a 2023 update, Pharmacol. Res., 187, 106552, \nhttps:\/\/doi.org\/10.1016\/j.phrs.2022.106552.","journal-title":"Pharmacol. Res."},{"key":"2703_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01055-9","volume":"14","author":"J. Cortes","year":"2021","unstructured":"Cortes, J., and Lang, F. (2021) Third-line therapy for chronic myeloid leukemia: current status and future directions, J.\u00a0Hematol. Oncol., 14, 44, \nhttps:\/\/doi.org\/10.1186\/s13045-021-01055-9.","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"2703_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00823-9","volume":"13","author":"J. Senapati","year":"2023","unstructured":"Senapati, J., Sasaki, K., Issa, G. C., Lipton, J. H., Radich, J. P., Jabbour, E., and Kantarjian, H.\u00a0M. (2023) Management of chronic myeloid leukemia in 2023\u2013common ground and common sense, Blood Cancer\u00a0J., 13, 58, \nhttps:\/\/doi.org\/10.1038\/s41408-023-00823-9.","journal-title":"Blood Cancer\u00a0J."},{"key":"2703_CR19","doi-asserted-by":"publisher","first-page":"635","DOI":"10.2147\/OTT.S189391","volume":"12","author":"F. H. Tan","year":"2019","unstructured":"Tan, F. H., Putoczki, T. L., Stylli, S. S., and Luwor, R.\u00a0B. (2019) Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies, Onco Targets Ther., 12, 635-645, \nhttps:\/\/doi.org\/10.2147\/OTT.S189391.","journal-title":"Onco Targets Ther."},{"key":"2703_CR20","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/nrd.2018.21","volume":"17","author":"F. M. Ferguson","year":"2018","unstructured":"Ferguson, F. M., and Gray, N. S. (2018) Kinase inhibitors: the road ahead, Nat. Rev. Drug Discov., 17, 353-377, \nhttps:\/\/doi.org\/10.1038\/nrd.2018.21.","journal-title":"Nat. Rev. Drug Discov."},{"key":"2703_CR21","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1021\/acs.jmedchem.8b00760","volume":"62","author":"E. Proschak","year":"2018","unstructured":"Proschak, E., Stark, H., and Merk, D. (2018) Polypharmacology by design: a medicinal chemist\u2019s perspective on multitargeting compounds, J.\u00a0Med. Chem., 62, 420-444, \nhttps:\/\/doi.org\/10.1021\/acs.jmedchem.8b00760.","journal-title":"J.\u00a0Med. Chem."},{"key":"2703_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.113511","volume":"221","author":"G. C. Arya","year":"2021","unstructured":"Arya, G. C., Kaur, K., and Jaitak, V. (2021) Isoxazole derivatives as anticancer agent: a review on synthetic strategies, mechanism of action and SAR studies, Eur.\u00a0J. Med. Chem., 221, 113511, \nhttps:\/\/doi.org\/10.1016\/j.ejmech.2021.113511.","journal-title":"Eur.\u00a0J. Med. Chem."},{"key":"2703_CR23","doi-asserted-by":"publisher","unstructured":"K\u00f6stler, W. J., and Zielinski, C. C. (2015) Targeting Receptor Tyrosine Kinases in Cancer, in Receptor Tyrosine Kinases: Structure, Functions and Role in Human Disease, New York, Spring, pp.\u00a078-225, \nhttps:\/\/doi.org\/10.1007\/978-1-4939-2053-2_10.","DOI":"10.1007\/978-1-4939-2053-2_10"},{"key":"2703_CR24","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.1038\/onc.2011.160","volume":"30","author":"G. Maurer","year":"2011","unstructured":"Maurer, G., Tarkowski, B., and Baccarini, M. (2011) Raf kinases in cancer-roles and therapeutic opportunities, Oncogene, 30, 3477-3488, \nhttps:\/\/doi.org\/10.1038\/onc.2011.160.","journal-title":"Oncogene"},{"key":"2703_CR25","doi-asserted-by":"publisher","first-page":"12256","DOI":"10.1002\/anie.201303207","volume":"52","author":"H. Sch\u00f6nherr","year":"2013","unstructured":"Sch\u00f6nherr, H., and Cernak, T. (2013) Profound methyl effects in drug discovery and a call for new C\u2013H methylation reactions, Angew. Chem. Int. Ed. Engl., 52, 12256-12267, \nhttps:\/\/doi.org\/10.1002\/anie.201303207.","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"2703_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/1758-2946-3-33","volume":"3","author":"N. M. O\u2019Boyle","year":"2011","unstructured":"O\u2019Boyle, N. M., Banck, M., James, C. A., Morley, C., Vandermeersch, T., and Hutchison, G.\u00a0R. (2011) Open Babel: An\u00a0open chemical toolbox, J.\u00a0Cheminform., 3, 33, \nhttps:\/\/doi.org\/10.1186\/1758-2946-3-33.","journal-title":"J.\u00a0Cheminform."},{"key":"2703_CR27","doi-asserted-by":"publisher","first-page":"10024","DOI":"10.1021\/ja00051a040","volume":"114","author":"A. K. Rapp\u00e9","year":"1992","unstructured":"Rapp\u00e9, A. K., Casewit, C. J., Colwell, K. S., Goddard, W.\u00a0A., III, and Skiff, W.\u00a0M. (1992) UFF, a full periodic table force field for molecular mechanics and molecular dynamics simulations, J.\u00a0Am. Chem. Soc., 114, 10024-10035, \nhttps:\/\/doi.org\/10.1021\/ja00051a040.","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"2703_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/srep42717","volume":"7","author":"A. Daina","year":"2017","unstructured":"Daina, A., Michielin, O., and Zoete, V. (2017) SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules, Sci. Rep., 7, 42717, \nhttps:\/\/doi.org\/10.1038\/srep42717.","journal-title":"Sci. Rep."},{"key":"2703_CR29","unstructured":"Center for Computational Structural Biology. MGL Tools. URL: https:\/\/ccsb.scripps.edu\/mgltools\/, Accessed October 21, 2023."},{"key":"2703_CR30","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"O. Trott","year":"2010","unstructured":"Trott, O., and Olson, A. J. (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading, J.\u00a0Comput. Chem., 31, 455-461, \nhttps:\/\/doi.org\/10.1002\/jcc.21334.","journal-title":"J.\u00a0Comput. Chem."},{"key":"2703_CR31","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/jcc.20084","volume":"25","author":"E. F. Pettersen","year":"2004","unstructured":"Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D.\u00a0M., Meng, E. C., and Ferrin, T.\u00a0E. (2004) UCSF Chimera\u00a0\u2013 a visualization system for exploratory research and analysis, J.\u00a0Comput. Chem., 25, 1605-1612, \nhttps:\/\/doi.org\/10.1002\/jcc.20084.","journal-title":"J.\u00a0Comput. Chem."},{"key":"2703_CR32","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1093\/bib\/bbz173","volume":"22","author":"C. Shen","year":"2021","unstructured":"Shen, C., Hu, Y., Wang, Z., Zhang, X., Zhong, H., Wang, G., Yao,\u00a0X., Xu, L., Cao, D., and Hou, T. (2021) Can machine learning consistently improve the scoring power of classical scoring functions? Insights into the role of machine learning in scoring functions, Brief. Bioinf., 22, 497-514, \nhttps:\/\/doi.org\/10.1093\/bib\/bbz173.","journal-title":"Brief. Bioinf."},{"key":"2703_CR33","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.1021\/ci2003889","volume":"51","author":"J. D. Durrant","year":"2011","unstructured":"Durrant, J. D., and McCammon, J. A. (2011) NNScore 2.0: A\u00a0neural-network receptor\u2013ligand scoring function, J.\u00a0Chem. Inf. Model., 51, 2897-2903, \nhttps:\/\/doi.org\/10.1021\/ci2003889.","journal-title":"J.\u00a0Chem. Inf. Model."},{"key":"2703_CR34","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.jmgm.2011.01.004","volume":"29","author":"J. D. Durrant","year":"2011","unstructured":"Durrant, J. D., and McCammon, J. A. (2011) BINANA: A\u00a0novel algorithm for ligand-binding characterization, J.\u00a0Mol. Graph. Model., 29, 888-893, \nhttps:\/\/doi.org\/10.1016\/j.jmgm.2011.01.004.","journal-title":"J.\u00a0Mol. Graph. Model."},{"key":"2703_CR35","unstructured":"Case, D.\u00a0A., Ben-Shalom, I.\u00a0Y., Brozell, S.\u00a0R., Cerutti, D.\u00a0S., Cheatham, T.\u00a0E.,\u00a03rd, Cruzeiro, V.\u00a0W.\u00a0D., Darden, T.\u00a0A., Duke, R.\u00a0E., Ghoreishi,\u00a0D., Gilson, M.\u00a0K., Gohlke,\u00a0H., Goetz, A.\u00a0W., Greene,\u00a0D., arris,\u00a0R , Homeyer,\u00a0N., Huang,\u00a0Y., Izadi,\u00a0S., Kovalenko,\u00a0A., Kurtzman,\u00a0T., Lee, T.\u00a0S., LeGrand,\u00a0S., Li,\u00a0P., Lin,\u00a0C., Liu,\u00a0J., Luchko,\u00a0T., Luo,\u00a0R., Mermelstein, D.\u00a0J., Merz, K.\u00a0M., Miao,\u00a0Y., Monard,\u00a0G., Nguyen,\u00a0C., Nguyen,\u00a0H., Omelyan,\u00a0I., Onufriev,\u00a0A., Pan,\u00a0F., Qi,\u00a0R., Roe, D.\u00a0R., Roitberg,\u00a0A., Sagui,\u00a0C., Schott-Verdugo,\u00a0S., Shen,\u00a0J., Simmerling, C.\u00a0L., Smith,\u00a0J., Salomon-Ferrer,\u00a0R., Swails,\u00a0J., Walker, R.\u00a0C., Wang,\u00a0J., Wei,\u00a0H., Wolf, R.\u00a0M., Wu,\u00a0X., Xiao,\u00a0L., York, D.\u00a0M., and Kollman, P.\u00a0A. (2018) AMBER 2018, University of California, San Francisco."},{"key":"2703_CR36","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1517\/17460441.2015.1032936","volume":"10","author":"S. Genheden","year":"2015","unstructured":"Genheden, S., and Ryde, U. (2015) The MM\/PBSA and MM\/GBSA methods to estimate ligand-binding affinity, Expert Opin. Drug. Discov., 10, 449-461, \nhttps:\/\/doi.org\/10.1517\/17460441.2015.1032936.","journal-title":"Expert Opin. Drug. Discov."},{"key":"2703_CR37","doi-asserted-by":"publisher","first-page":"8408","DOI":"10.1021\/jp404160y","volume":"117","author":"L. Xu","year":"2013","unstructured":"Xu, L., Sun, H., Li, Y., Wang, J., and Hou, T. (2013) Assessing the performance of MM\/PBSA and MM\/GBSA methods. 3.\u00a0The\u00a0impact of force fields and ligand charge models, J.\u00a0Phys. Chem.\u00a0B, 117, 8408-8421, \nhttps:\/\/doi.org\/10.1021\/jp404160y.","journal-title":"J.\u00a0Phys. Chem.\u00a0B"},{"key":"2703_CR38","doi-asserted-by":"publisher","first-page":"16719","DOI":"10.1039\/c4cp01388c","volume":"16","author":"H. Sun","year":"2014","unstructured":"Sun, H., Li, Y., Tian, S., Xu, L., and Hou, T. (2014) Assessing the performance of MM\/PBSA and MM\/GBSA methods. 4.\u00a0Accuracies of MM\/PBSA and MM\/GBSA methodologies evaluated by various simulation protocols using PDBbind data set, Phys. Chem. Chem. Phys., 16, 16719-16729, \nhttps:\/\/doi.org\/10.1039\/c4cp01388c.","journal-title":"Phys. Chem. Chem. Phys."},{"key":"2703_CR39","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1134\/S107042801808016X","volume":"54","author":"Z. V. Ignatovich","year":"2018","unstructured":"Ignatovich, Z. V., Ermolinskaya, A. L., Kletskov, A.\u00a0V., Potkin, V. I., and Koroleva, E.\u00a0V. (2018) Synthesis of new amides of isoxazole-and isothiazole-substituted carboxylic acids containing an arylaminopyrimidine fragment, Russ.\u00a0J. Org. Chem., 54, 1218-1222, \nhttps:\/\/doi.org\/10.1134\/S107042801808016X.","journal-title":"Russ.\u00a0J. Org. Chem."},{"key":"2703_CR40","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1093\/humrep\/dem011","volume":"22","author":"S. Al-Nasiry","year":"2007","unstructured":"Al-Nasiry, S., Geusens, N., Hanssens, M., Luyten, C., and Pijnenborg, R. (2007) The\u00a0use of Alamar Blue assay for quantitative analysis of viability, migration and invasion of choriocarcinoma cells, Hum. Reprod., 22, 1304-1309, \nhttps:\/\/doi.org\/10.1093\/humrep\/dem011.","journal-title":"Hum. Reprod."},{"key":"2703_CR41","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1038\/nsmb.2891","volume":"21","author":"R. V. Agafonov","year":"2014","unstructured":"Agafonov, R. V., Wilson, C., Otten, R., Buosi, V., and Kern, D. (2014) Energetic dissection of Gleevec\u2019s selectivity toward human tyrosine kinases, Nat. Struct. Mol. Biol., 21, 848-853, \nhttps:\/\/doi.org\/10.1038\/nsmb.2891.","journal-title":"Nat. Struct. Mol. Biol."},{"key":"2703_CR42","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.ddtec.2004.11.007","volume":"1","author":"C. A. Lipinski","year":"2004","unstructured":"Lipinski, C. A. (2004) Lead- and drug-like compounds: the rule-of-five revolution, Drug Discov. Today Technol., 1, 337-341, \nhttps:\/\/doi.org\/10.1016\/j.ddtec.2004.11.007.","journal-title":"Drug Discov. Today Technol."},{"key":"2703_CR43","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/s0169-409x(00)00129-0","volume":"46","author":"C. A. Lipinski","year":"2001","unstructured":"Lipinski, C. A., Lombardo, F., Dominy, B. W., and Feeney, P. J. (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings, Adv. Drug Deliv. Rev., 46, 3-26, \nhttps:\/\/doi.org\/10.1016\/s0169-409x(00)00129-0.","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2703_CR44","doi-asserted-by":"publisher","first-page":"W257","DOI":"10.1093\/nar\/gky318","volume":"46","author":"P. Banerjee","year":"2018","unstructured":"Banerjee, P., Eckert, A. O., Schrey, A. K., and Preissner, R. (2018) ProTox-II: a\u00a0webserver for the prediction of toxicity of chemicals, Nucleic Acids Res., 46, W257-W263, \nhttps:\/\/doi.org\/10.1093\/nar\/gky318.","journal-title":"Nucleic Acids Res."},{"key":"2703_CR45","doi-asserted-by":"publisher","first-page":"572","DOI":"10.2174\/1381612822666151125000550","volume":"22","author":"M. Hassan Baig","year":"2016","unstructured":"Hassan Baig, M., Ahmad, K., Roy, S., Mohammad Ashraf, J., Adil, M., Siddiqui, M. H., Khan, S., Kamal, M.\u00a0A., Provazn\u00edk, I., and Choi, I. (2016) Computer aided drug design: success and limitations, Curr. Pharm. Des., 22, 572-581, \nhttps:\/\/doi.org\/10.2174\/1381612822666151125000550.","journal-title":"Curr. Pharm. Des."},{"key":"2703_CR46","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.4155\/fmc-2016-0161","volume":"8","author":"P. V. Desai","year":"2016","unstructured":"Desai, P. V. (2016) The\u00a0integration of computational chemistry during drug discovery to drive decisions: are we there yet? Future Med. Chem., 8, 1717-1720, \nhttps:\/\/doi.org\/10.4155\/fmc-2016-0161.","journal-title":"Future Med. Chem."},{"key":"2703_CR47","doi-asserted-by":"publisher","first-page":"992","DOI":"10.18632\/oncotarget.27513","volume":"11","author":"J. J. Jimenez","year":"2020","unstructured":"Jimenez, J. J., Chale, R. S., Abad, A. C., and Schally, A.\u00a0V. (2020) Acute promyelocytic leukemia (APL): a review of the literature, Oncotarget, 11, 992-1003, \nhttps:\/\/doi.org\/10.18632\/oncotarget.27513.","journal-title":"Oncotarget"},{"key":"2703_CR48","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1111\/cbdd.12983","volume":"90","author":"P. Parcha","year":"2017","unstructured":"Parcha, P., Sarvagalla, S., Madhuri, B., Pajaniradje, S., Baskaran, V., Coumar, M.\u00a0S., and Rajasekaran, B. (2017) Identification of natural inhibitors of Bcr-Abl for the treatment of chronic myeloid leukemia, Chem. Biol. Drug Des., 90, 596-608, \nhttps:\/\/doi.org\/10.1111\/cbdd.12983.","journal-title":"Chem. Biol. Drug Des."},{"key":"2703_CR49","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1177\/1947601912462126","volume":"3","author":"E. P. Reddy","year":"2012","unstructured":"Reddy, E. P., and Aggarwal, A. K. (2012) The\u00a0ins and outs of bcr-abl inhibition, Genes Cancer, 3, 447-454, \nhttps:\/\/doi.org\/10.1177\/1947601912462126.","journal-title":"Genes Cancer"},{"key":"2703_CR50","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V106.11.3365.3365","volume":"106","author":"P. W. Manley","year":"2005","unstructured":"Manley, P. W., Cowan-Jacob, S. W., Fendrich, G., and Mestan, J. (2005) Molecular interactions between the highly selective pan-Bcr-Abl inhibitor, AMN107, and the tyrosine kinase domain of Abl, Blood, 106, 3365, \nhttps:\/\/doi.org\/10.1182\/blood.V106.11.3365.3365.","journal-title":"Blood"},{"key":"2703_CR51","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.jmgm.2017.04.005","volume":"74","author":"F. Sohraby","year":"2017","unstructured":"Sohraby, F., Bagheri, M., Aliyar, M., and Aryapour, H. (2017) In\u00a0silico drug repurposing of FDA-approved drugs to predict new inhibitors for drug resistant T315I mutant and wild-type BCR-ABL1: a\u00a0virtual screening and molecular dynamics study, J.\u00a0Mol. Graph. Model., 74, 234-240, \nhttps:\/\/doi.org\/10.1016\/j.jmgm.2017.04.005.","journal-title":"J.\u00a0Mol. Graph. Model."},{"key":"2703_CR52","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1142\/S273741652150023X","volume":"20","author":"Y. S. \u0130\u015f","year":"2021","unstructured":"\u0130\u015f, Y. S. (2021) Elucidation of ligand\/protein interactions between BCR-ABL tyrosine kinase and some commercial anticancer drugs via DFT methods, J.\u00a0Comput. Biophys. Chem., 20, 433-447, \nhttps:\/\/doi.org\/10.1142\/S273741652150023X.","journal-title":"J.\u00a0Comput. Biophys. Chem."},{"key":"2703_CR53","doi-asserted-by":"publisher","DOI":"10.1186\/s12864-017-3503-2","volume":"18","author":"H. H. Hsu","year":"2017","unstructured":"Hsu, H. H., Hsu, Y. C., Chang, L. J., and Yang, J.\u00a0M. (2017) An\u00a0integrated approach with new strategies for QSAR models and lead optimization, BMC Genom., 18, 104, \nhttps:\/\/doi.org\/10.1186\/s12864-017-3503-2.","journal-title":"BMC Genom."},{"key":"2703_CR54","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbaa374","volume":"22","author":"L. Fu","year":"2021","unstructured":"Fu, L., Yang, Z. Y., Yang, Z. J., Yin, M. Z., Lu, A.\u00a0P., Chen, X., Liu, S., Hou, T. J., and Cao, D. S. (2021) QSAR-assisted-MMPA to expand chemical transformation space for lead optimization, Brief. Bioinform., 22, bbaa374, \nhttps:\/\/doi.org\/10.1093\/bib\/bbaa374.","journal-title":"Brief. Bioinform."},{"key":"2703_CR55","doi-asserted-by":"publisher","first-page":"900","DOI":"10.2174\/1871520623666230110114620","volume":"23","author":"M. S. Ayaz","year":"2023","unstructured":"Ayaz, M. S., Bhupal, R., Sharma, P., Sahu, A., Singh, P., Gupta, G. D., and Asati, V. (2023) Recent updates on structural aspects of ALK inhibitors as an anticancer agent, Anti-Cancer Agents Med. Chem., 23, 900-921, \nhttps:\/\/doi.org\/10.2174\/1871520623666230110114620.","journal-title":"Anti-Cancer Agents Med. Chem."}],"container-title":["Biochemistry (Moscow)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1134\/S0006297924060099.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1134\/S0006297924060099","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1134\/S0006297924060099.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:19:31Z","timestamp":1773620371000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1134\/S0006297924060099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":55,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["2703"],"URL":"https:\/\/doi.org\/10.1134\/s0006297924060099","relation":{},"ISSN":["0006-2979","1608-3040"],"issn-type":[{"value":"0006-2979","type":"print"},{"value":"1608-3040","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"27 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This work does not contain any studies involving human and animal subjects. The\u00a0authors of this work declare that they have no\u00a0conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics declarations"}}]}}